Neovacs appoints Piers Whitehead as VP of Corporate Development
03-Sep-2009
- France
Prior to joining Neovacs, Mr. Whitehead was a consultant providing counsel to biotechnology companies on business and corporate development. Previously, he was Vice President of Business and Corporate Development for VaxGen Inc., a public US biotechnology company, and prior to that he was a Vice President of Mercer Management Consulting (now Oliver Wyman), where he headed that firm’s San Francisco office. He graduated from Oriel College, Oxford.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
Eproplan GmbH - Stuttgart, Germany
Go to page
Verus Pharmaceuticals divestiture of Pediatric Asthma development programs to AstraZeneca
Go to page
Thomas Recording GmbH - Gießen, Germany
Go to page
MIP Pharma Austria GmbH - Innsbruck, Austria
Go to page
EUROBIO LABORATOIRES - Orsay, France
Go to page